Search research articles
Contact Us
Filters
Showing results (21-30 of 52) with videos related to
Page
of 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 17, 2008
Tris (dibenzylideneacetone) dipalladium, a N-myristoyltransferase-1 inhibitor, is effective against melanoma growth in vitro and in vivo
Sulochana S Bhandarkar, Jacqueline Bromberg, Carol Carrillo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 4, 2007
Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer
Monica N Fornier, Andrew D Seidman, Diana Lake, et al.
Cancer Research
|
December 28, 2013
Oligodendrocyte progenitor cells promote neovascularization in glioma by disrupting the blood-brain barrier
Yujie Huang, Caitlin Hoffman, Prajwal Rajappa, et al.
Cancer Research
|
March 3, 2006
Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3
Kenneth Leslie, Cynthia Lang, Geeta Devgan, et al.
Plos One
|
December 6, 2011
Stat3 mediates expression of autotaxin in breast cancer
Janeen Azare, Ashley Doane, Kenneth Leslie, et al.
Research Square
|
June 17, 2024
Intratumoral Fc-optimized agonistic CD40 antibody induces tumor rejection and systemic antitumor immunity in patients with metastatic cancer
Juan C Osorio, David A Knorr, Polina Weitzenfeld, et al.
Oncogene
|
April 18, 2002
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
Guilian Niu, Kenneth L Wright, Mei Huang, et al.
Clinical Breast Cancer
|
April 23, 2018
Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer
Patrick G Morris, Selene Rota, Karen Cadoo, et al.
Cancer Cell
|
August 15, 2025
Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer
Juan C Osorio, David A Knorr, Polina Weitzenfeld, et al.
Biology
|
September 28, 2021
Pilot Study of Anti-Th2 Immunotherapy for the Treatment of Breast Cancer-Related Upper Extremity Lymphedema
Babak J Mehrara, Hyeung Ju Park, Raghu P Kataru, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 52) with videos related to
Sort By:
Page
of 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 17, 2008
Tris (dibenzylideneacetone) dipalladium, a N-myristoyltransferase-1 inhibitor, is effective against melanoma growth in vitro and in vivo
Sulochana S Bhandarkar, Jacqueline Bromberg, Carol Carrillo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 4, 2007
Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer
Monica N Fornier, Andrew D Seidman, Diana Lake, et al.
Cancer Research
|
December 28, 2013
Oligodendrocyte progenitor cells promote neovascularization in glioma by disrupting the blood-brain barrier
Yujie Huang, Caitlin Hoffman, Prajwal Rajappa, et al.
Cancer Research
|
March 3, 2006
Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3
Kenneth Leslie, Cynthia Lang, Geeta Devgan, et al.
Plos One
|
December 6, 2011
Stat3 mediates expression of autotaxin in breast cancer
Janeen Azare, Ashley Doane, Kenneth Leslie, et al.
Research Square
|
June 17, 2024
Intratumoral Fc-optimized agonistic CD40 antibody induces tumor rejection and systemic antitumor immunity in patients with metastatic cancer
Juan C Osorio, David A Knorr, Polina Weitzenfeld, et al.
Oncogene
|
April 18, 2002
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
Guilian Niu, Kenneth L Wright, Mei Huang, et al.
Clinical Breast Cancer
|
April 23, 2018
Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer
Patrick G Morris, Selene Rota, Karen Cadoo, et al.
Cancer Cell
|
August 15, 2025
Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer
Juan C Osorio, David A Knorr, Polina Weitzenfeld, et al.
Biology
|
September 28, 2021
Pilot Study of Anti-Th2 Immunotherapy for the Treatment of Breast Cancer-Related Upper Extremity Lymphedema
Babak J Mehrara, Hyeung Ju Park, Raghu P Kataru, et al.
Page
of 6